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QUESTIONS
1. Describe the epidemiology and diagnosis of melanoma.
2. What were the proposed hypothesis and rationale for the study?
3. What methods were used, and how did these methods affect the outcome of the study?
4. What were the results of the study?
5. What were the conclusions and implications of the study?
The oft-quoted line “It is what I say it is” is commonly applied to dermato-
logic diagnoses, and this saying can also be applied to histologic diagnoses. 
Whether evaluating a biopsy specimen at a single moment during the course 
of a disease accurately predicts the biologic course of that lesion is not always 
clear. This is especially true in the diagnosis of melanoma, in which excision 
of a potentially fatal lesion obviates learning its true biological potential. The 
alternative option—to leave untreated a lesion with unknown biologic poten-
tial—is unacceptable, because doing so places patients at risk (melanoma 
is predicted to kill nearly 9,000 Americans this year alone (American Cancer 
Society, 2009)). Thus, the overarching goal for melanoma clinicians is to accu-
rately diagnose and subsequently excise true melanomas while leaving the 
remainder untreated.
Clinicians and pathologists utilize a variety of techniques to diagnose 
melanoma. To aid diagnosis, pathologists rely on cytologic and architectural 
features in concert with immunohistochemistry. But can they do better? 
Previous work utilized microarray data, which illuminated differences between gene expression in benign lesions 
and advanced melanoma, to identify several candidate markers that could assist in this process (Talantov et al., 
2005). In a follow-up study described in this issue, Alexandrescu et al. (2010) employed three candidate mark-
ers—silver homologue (SILV), the prostate differentiation marker PLAB (GDF15), and L1 cell adhesion molecule 
(L1CAM)—to examine melanomas from paraffin-embedded specimens. Using 193 specimens that had been diag-
nosed as benign nevi, atypical nevi, and melanoma by a consensus panel of expert dermatopathologists, the inves-
tigators found that employing SILV as a single molecular test was the best predictor of a melanoma diagnosis as 
determined by the dermatopathologists.
Using the following questions, we examine this paper, as well as the subject of melanoma diagnosis, in greater 
detail. For brief answers, please refer to the supplementary information online <http://www.nature.com/jid/journal/
v130/n7/suppinfo/jid2010157s1.html>.
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